MCAR15-Vδ2T cells resulted in complete remissions in all 5/5 mice through day 180 without any signs of GvHD, highlighting the benefit of IL-15 engineering in long-term intraperitoneal tumor growth inhibition (Fig. 6e). Here, IL15 is linked to neoplasm.